NHHS Health Alert - COVID-19 Pandemic, Update # 58 Paxlovid and Molnupiravir Distribution

On March 10, 2022, NH DHHS issued a health alert regarding Paxlovid and Molnupiravir Distribution

Key Points and Recommendations:

• Providers should continue to refer to the NIH and IDSA treatment guidelines for decisions regarding the multiple outpatient therapies available to treat patients with COVID-19.
• The two oral antiviral medications Paxlovid and molnupiravir are now being allocated to certain commercial pharmacies in New Hampshire, and are available through routine prescribing.
  • Molnupiravir can currently be prescribed through certain Walgreens, CVS, and Rite Aid pharmacies.
  • Paxlovid will be available at Walgreens pharmacy locations over the next two weeks (Table 1 below).
  • The federal COVID-19 Test to Treat program is also allocating Paxlovid and molnupiravir to certain CVS Minute Clinic locations starting this week (Table 2 below).
  • As allocations increase, distribution will expand to other pharmacy locations. Providers should check the federal Health and Human Services (HHS) COVID-19 Therapeutics Locator for availability of therapeutics by location.
• Providers who are prescribing Paxlovid and Molnupiravir must be familiar with prescribing requirements and review the following:
  • Paxlovid:
    • FDA’s Fact Sheet for Healthcare Providers
    • FDA’s Fact Sheet for Patients, Parents and Caregivers (must be provided to patients and caregivers prior to prescribing Paxlovid)
  • Molnupiravir:
    • FDA’s Fact Sheet for Healthcare Providers
    • FDA’s Fact Sheet for Patients and Caregivers (must be provided to patients and caregivers prior to prescribing molnupiravir)
• For more information, review the previous HAN communications:
  • NH COVID-19 HAN #52
  • NH COVID-19 HAN #54
  • CDC HAN “Using Therapeutics to Prevent and Treat COVID-19